Can Metronidazole Treat Chronic Colitis?

Metronidazole is not considered a first-line or standard treatment for chronic colitis. While it is an effective antimicrobial agent against anaerobic bacteria and certain protozoa, chronic colitis—particularly when referring to inflammatory bowel diseases such as ulcerative colitis or Crohn’s disease—is primarily driven by dysregulated immune responses rather than infection. Therefore, therapy focuses on immunomodulation (e.g., 5-aminosalicylates, corticosteroids, biologics) rather than antimicrobial agents.

In select cases—such as colitis associated with Clostridioides difficile infection or parasitic infestations like Entamoeba histolytica—metronidazole may be indicated. However, these represent infectious etiologies, not idiopathic chronic colitis. Its use in non-infectious, immune-mediated forms lacks robust clinical evidence and is generally discouraged due to potential adverse effects—including peripheral neuropathy, metallic taste, and gastrointestinal intolerance—and the risk of promoting antimicrobial resistance.

Clinicians evaluating patients with chronic colitis must first establish an accurate diagnosis through endoscopy, histopathology, and microbiologic testing to rule out infectious causes. Empiric metronidazole administration without confirmed infection is inappropriate and may delay appropriate immunosuppressive or targeted therapy.